Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Non-Current Assets: 2014-2025

Historic Non-Current Assets for CytomX Therapeutics (CTMX) over the last 10 years, with Sep 2025 value amounting to $9.0 million.

  • CytomX Therapeutics' Non-Current Assets fell 38.94% to $9.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.0 million, marking a year-over-year decrease of 38.94%. This contributed to the annual value of $13.2 million for FY2024, which is 29.85% down from last year.
  • According to the latest figures from Q3 2025, CytomX Therapeutics' Non-Current Assets is $9.0 million, which was down 13.41% from $10.4 million recorded in Q2 2025.
  • CytomX Therapeutics' Non-Current Assets' 5-year high stood at $131.4 million during Q2 2021, with a 5-year trough of $9.0 million in Q3 2025.
  • Moreover, its 3-year median value for Non-Current Assets was $16.1 million (2024), whereas its average is $16.0 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first surged by 273.41% in 2021, then plummeted by 79.87% in 2022.
  • Quarterly analysis of 5 years shows CytomX Therapeutics' Non-Current Assets stood at $29.1 million in 2021, then dropped by 18.28% to $23.8 million in 2022, then decreased by 20.74% to $18.9 million in 2023, then fell by 29.85% to $13.2 million in 2024, then plummeted by 38.94% to $9.0 million in 2025.
  • Its Non-Current Assets stands at $9.0 million for Q3 2025, versus $10.4 million for Q2 2025 and $11.9 million for Q1 2025.